Rebecca Forand

2 months ago | healio.com | Rebecca Forand |Kristen Dowd |Valerie D. Callender |Shawn G. Kwatra

Key takeaways: Diverse patient populations are needed for accurate clinical testing. Four experts discussed the challenges to creating diverse teams and recruiting diverse patients. ORLANDO — Increasing diversity in research, from basic and translational to clinical science, is more important than ever and clinicians need to meet people where they are to do so, according to a panel discussion here. John E.

Mar 8, 2025 | healio.com | Rebecca Forand |Jill S. Waibel

Key takeaways: Burn and trauma scars can be extensive and difficult for patients. Jill S. Waibel, MD, gives pearls on how to best approach these cases. ORLANDO — Innovations in treating burn and trauma scars in recent years include updated laser technology, giving practitioners options to help in these difficult cases, according to a speaker here. “When I look at a scar, I think about un-coloring a picture. What do I want it to look like when I’m done?” Jill S.

Mar 8, 2025 | healio.com | Rebecca Forand |Kristen Dowd |Daniel Butler

Key takeaways: Adults aged older than 50 years are most likely to visit a dermatologist for itch. Rather than dismissing it as dry skin, dermatologists should look at the varied reasons itch can occur in this population. ORLANDO — Itching in older patients should not be dismissed as simply dry skin, but rather approached as a complex problem involving numerous causes, according to a speaker at the American Academy of Dermatology Annual Meeting.

Mar 7, 2025 | healio.com | Rebecca Forand |Kristen Dowd |Seemal R. Desai

Key takeaways: Current AAD President Seemal R. Desai, MD, FAAD, addressed the Skin of Color Society regarding leadership. Desai touted the importance of taking one’s individual journey toward leadership roles. ORLANDO — Seemal R. Desai, MD, FAAD, who is finishing his term as American Academy of Dermatology president, took time to reflect on his own leadership journey and inspire future leaders at the Skin of Color Society Scientific Symposium.

Feb 17, 2025 | healio.com | Rebecca Forand |Kristen Dowd

Key takeaways: This phase 3b clinical trial focused on safety and efficacy of the anti-IL-23 inhibitor in scalp psoriasis. Patients taking tildrakizumab had scalp improvement by 16 weeks, which continued through week 52. Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first “dedicated trial” to demonstrate sustainable efficacy of an anti-interleukin-23 inhibitor for the condition.